Triple-negative breast cancer (TNBC) is the most malignant subtype of breast cancer (BC)
with a poor prognosis. Current treatment options are limited to surgery, adjuvant …

Tumour heterogeneity and a long-standing paucity of effective therapies other than
chemotherapy have contributed to triple-negative breast cancer (TNBC) being the subtype …

Treatment of triple-negative breast cancer (TNBC) remains challenging. Deciphering the
orchestration of metabolic pathways in regulating ferroptosis will provide new insights into …

Triple-negative breast cancer (TNBC) encompasses a heterogeneous group of
fundamentally different diseases with different histologic, genomic, and immunologic …

Immunotherapy has achieved limited success in patients with triple-negative breast cancer
(TNBC), an aggressive disease with a poor prognosis. Commensal microbiota have been …

The therapeutic effect of highly malignant triple negative breast cancer (TNBC) is negatively
affected by the formation of tumor cell resistant clone and the severe toxicity of …

Background Immunotherapy has recently emerged as a treatment strategy which stimulates
the human immune system to kill tumor cells. Tumor immunotherapy is based on immune …

Metabolic reprogramming is a hallmark of cancer. However, systematic characterizations of
metabolites in triple-negative breast cancer (TNBC) are still lacking. Our study profiled the …

Triple-negative breast cancer (TNBC) remains an unmet medical challenge. We investigated
metabolic dysregulation in TNBCs by using our multi-omics database (n= 465, the largest to …

Abstract Hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-
negative (HER2−) breast cancer is the most prevalent type of breast cancer, in which …